Trials
Search / Trial NCT06438861

Role of Combination Therapy in Women With Refractory Overactive Bladder

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · May 29, 2024

Trial Information

Current as of February 14, 2025

Not yet recruiting

Keywords

Refractory Overactive Bladder Syndrome

ClinConnect Summary

The study will be a prospective double-blinded randomized control trial to examine the effect of administering vibegron versus placebo in conjunction with intradetrusor onabotulinumtoxinA injections for the management of refractory OAB. Patients who present to the University of Alabama at Birmingham urogynecology practice with refractory OAB undergoing the standard 100U intradetrusor onabotulinumtoxinA will be offered enrollment to either the onabotulinumtoxinA plus vibegron or the onabotulinumtoxinA plus placebo groups. Prior to onabotulinumtoxinA injections, patients' baseline demographic...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • 1. Women undergoing intradetrusor botulinum injections for refractory OAB
  • 2. Age 18 years old or greater
  • 3. Fluency and literacy in English
  • 4. Capacity to provide consent
  • Exclusion Criteria:
  • 1. Allergy to Vibegron
  • 2. Currently pregnant or planning to become pregnant
  • 3. Breastfeeding
  • 4. Current digoxin use

About University Of Alabama At Birmingham

The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0